Cancer research is a major area of excellence at Barts and The London, QMUL. We are founding partner of the CRUK City of London Centre, which is revolutionising the way cancer research is conducted in London. Using our scale to define nich subtypes through meticulously phenotyped cohorts that accelerate clinical trials and outcomes and enable research for unmet need in adult and paediatric oncology. We administer several programmes from Cancer Research UK and multiple projects and fellowships, including our Barts Cancer Centre which received £10 million an official CRUK Centre. Almost a doubling of its previous investment, the funds support research facilities and training programmes, with the aim to of getting treatments and diagnostics to cancer patients sooner. Meanwhile, our Experimental Cancer Medicine Centre has been supported with an investment of £2.4m, to focus on the treatment of cancers with unmet need, including pancreatic, oesophageal and mesothelioma.
Our Centre for Cancer Prevention conducts research into the prevention of cancer with particular focus on preventive therapy and screening. Major successes include the impact of the IBIS-II trial, which studied almost 4,000 postmenopausal women at high risk of breast cancer, finding that those treated with anastrozole were 53% less likely to develop breast cancer, and that the drug was more effective than tamoxifen, with fewer side effects.
We host and have renewed our Brain Tumour Research Centre of Excellence with £3 million and a further £1.6 million of funding from the Brain Tumour Research charity, which aims to elucidate the epigenome of glioblastoma multiforme, the most common and aggressive type of malignant brain tumour. We have international leadership in a rare form of hereditary brain tumour in a rare form of hereditary brain tumour (familial isolated pituitary adenoma), for which we have identified the gene alteration and developed assays to enable intervention.
We also hold world leadership in applied and translational research in skin cancer, through our Centre for Cell Biology and Cutaneous Research. A research focus is epithelial cancer including non-melanoma skin cancer, malignant melanoma, head and neck cancer.